Table 2 Antibiotics used on inpatients aged > 28 days to 15 years during the period January – December 2015
From: Antibiotic use on paediatric inpatients in a teaching hospital in the Gambia, a retrospective study
Antibiotic | DoT | DoT/1000PD (Total PD = 4045) | Proportion of patients treated with the antibiotic (n = 917, %) | Age | ||
|---|---|---|---|---|---|---|
under 5 years n = 630, % | 5 years and more n = 287, % | P Value* | ||||
J01G aminoglycosides | ||||||
Gentamicin | 664 | 164.2 | 133, 14.5% | 121, 19.2% | 12, 4.2% | < 0.001 |
Neomycin | 33 | 8.2 | 5, 0.5% | 5, 0.8% | 0 | 0.154 |
J01D cephalosporins | ||||||
Cefriaxone | 490 | 121.1 | 117, 12.8% | 86, 13.7% | 31, 10.8% | 0.982 |
Cefalexin | 16 | 4.0 | 3, 0.3% | 3, 0.5% | 0 | 0.231 |
Cefpodoxime | 1 | 0.2 | 1, 0.1% | 1, 0.2% | 0 | 0.551 |
J01C Beta-lactam antibacterials, Penicillins | ||||||
Ampicillin | 416 | 103.0 | 179, 19.5% | 140, 22.2% | 39, 13.6% | 0.003 |
Penicillin-G | 416 | 103.0 | 92, 10.0% | 64, 10.2% | 28, 9.8% | 0.077 |
Cloxacillin | 200 | 49.4 | 44, 4.8% | 39, 6.2% | 5, 1.7% | 0.054 |
Amoxicillin | 150 | 37.1 | 31, 3.4% | 21, 3.3% | 10, 3.5% | 0.847 |
Amoxicillin-clavulanic | 16 | 4.0 | 1, 0.1% | 0 | 1, 0.3% | 0.017 |
Flucloxacillin | 6 | 1.4 | 1, 0.1% | 1, 0.2% | 0 | 0.551 |
J01B Amphenicols | ||||||
Chloramphenicol | 129 | 31.9 | 50, 5.5% | 33, 5.2% | 17, 5.9% | 0.078 |
J01XD Imidazole derivatives | ||||||
Metronidazole | 73 | 18.0 | 9, 1.0% | 5, 0.8% | 4, 1.4% | 0.209 |
J01 M Quinolones | ||||||
Ciprofloxacin | 35 | 8.7 | 10, 1.1% | 3, 0.5% | 7, 2.4% | < 0.001 |
J01A Tetracyclines | ||||||
Tetracycline | 26 | 6.4 | 1, 0.1% | 0 | 1, 0.3% | 0.093 |
J01XA glycopeptides | ||||||
Vancomycin | 24 | 5.9 | 1, 0.1% | 1, 0.2% | 0 | 0.551 |
J01FA macrolides | ||||||
Erythromycin | 7 | 1.7 | 3, 0.3% | 2, 0.3% | 1, 0.3% | 0.398 |
J01E Sulfonamides and Trimethoprim | ||||||
Co-trimoxazole | 6 | 1.4 | 1, 0.1% | 1, 0.2% | 0 | 0.551 |
J01XE Nitrofuran derivatives | ||||||
Nitorfurantoin | 5 | 1.2 | 1, 0.1% | 0 | 1, 0.3% | 0.093 |
Total | 2713 | 670.7 | – | – | – | – |